<DOC>
	<DOCNO>NCT00699153</DOCNO>
	<brief_summary>Evaluation clinical safety efficacy loteprednol etabonate ophthalmic base , compare vehicle treatment inflammation follow cataract surgery .</brief_summary>
	<brief_title>Loteprednol Etabonate Ophthalmic Base v Vehicle Treatment Inflammation Following Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Subjects least 18 year age Subjects ability understand sign inform consent form provide Health Insurance Portability Accountability Act ( HIPAA ) authorization . Subjects candidate routine , uncomplicated cataract surgery . Subjects childbearing potential subject negative urine pregnancy test result screen . Subjects must willing able comply treatment follow procedure . Subjects know hypersensitivity contraindication study drug component . Subjects history presence chronic generalize systemic disease investigator feel might increase risk subject compound result study . Subjects severe/serious ocular condition , unstable medical condition , Investigator 's opinion , may preclude study treatment followup . Subjects elevate intraocular pressure ( &gt; /= 21 mm Hg ) , uncontrolled glaucoma , treat glaucoma study eye . Subjects monocular pinholed Snellen VA 20/200 bad nonstudy eye . Subjects ocular surgery study eye within 3 month fellow eye within 2 week prior screen visit . Women pregnant breast feeding . Subjects participate investigational drug device study within last 30 day . Subjects previously randomize study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>